Ascendis Pharma A/S (ASND) Scheduled to Post Quarterly Earnings on Thursday

Ascendis Pharma A/S (NASDAQ:ASND) is set to issue its quarterly earnings data on Thursday, April 25th.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.15) by $0.49. The company had revenue of $148.62 million during the quarter, compared to analysts’ expectations of $97.02 million. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. On average, analysts expect Ascendis Pharma A/S to post $-4 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ascendis Pharma A/S Stock Performance

Ascendis Pharma A/S stock opened at $144.83 on Wednesday. The business’s 50-day simple moving average is $149.15 and its 200-day simple moving average is $125.48. The firm has a market capitalization of $8.43 billion, a PE ratio of -15.66 and a beta of 0.50. Ascendis Pharma A/S has a 52 week low of $66.03 and a 52 week high of $161.00.

Analyst Ratings Changes

ASND has been the topic of a number of recent analyst reports. Wedbush lifted their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the stock an “outperform” rating in a research note on Thursday, February 8th. Morgan Stanley restated an “equal weight” rating and set a $116.00 price target on shares of Ascendis Pharma A/S in a research note on Monday. Cantor Fitzgerald restated an “overweight” rating and set a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday, April 18th. Citigroup boosted their price target on Ascendis Pharma A/S from $146.00 to $182.00 and gave the company a “buy” rating in a research note on Thursday, February 8th. Finally, JPMorgan Chase & Co. boosted their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the company an “overweight” rating in a research note on Tuesday, April 2nd. Two analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.